1. Home
  2. CSPI vs PBYI Comparison

CSPI vs PBYI Comparison

Compare CSPI & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSPI
    SELLHOLDBUYas of 3 hours ago
  • PBYI
    SELLHOLDBUYas of 3 hours ago
  • Stock Information
  • Founded
  • CSPI 1968
  • PBYI 2010
  • Country
  • CSPI United States
  • PBYI United States
  • Employees
  • CSPI N/A
  • PBYI N/A
  • Industry
  • CSPI EDP Services
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • CSPI Technology
  • PBYI Health Care
  • Exchange
  • CSPI Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • CSPI 146.9M
  • PBYI 147.8M
  • IPO Year
  • CSPI 1987
  • PBYI N/A
  • Fundamental
  • Price
  • CSPI $13.76
  • PBYI $2.88
  • Analyst Decision
  • CSPI
  • PBYI Strong Buy
  • Analyst Count
  • CSPI 0
  • PBYI 1
  • Target Price
  • CSPI N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • CSPI 28.2K
  • PBYI 360.5K
  • Earning Date
  • CSPI 05-07-2025
  • PBYI 05-01-2025
  • Dividend Yield
  • CSPI 0.81%
  • PBYI N/A
  • EPS Growth
  • CSPI N/A
  • PBYI 37.78
  • EPS
  • CSPI 0.02
  • PBYI 0.62
  • Revenue
  • CSPI $55,514,000.00
  • PBYI $230,468,000.00
  • Revenue This Year
  • CSPI N/A
  • PBYI N/A
  • Revenue Next Year
  • CSPI N/A
  • PBYI N/A
  • P/E Ratio
  • CSPI $793.10
  • PBYI $4.70
  • Revenue Growth
  • CSPI N/A
  • PBYI N/A
  • 52 Week Low
  • CSPI $10.76
  • PBYI $2.23
  • 52 Week High
  • CSPI $21.95
  • PBYI $6.06
  • Technical
  • Relative Strength Index (RSI)
  • CSPI 37.32
  • PBYI 36.75
  • Support Level
  • CSPI $14.80
  • PBYI $3.14
  • Resistance Level
  • CSPI $16.55
  • PBYI $3.18
  • Average True Range (ATR)
  • CSPI 0.74
  • PBYI 0.18
  • MACD
  • CSPI -0.13
  • PBYI -0.07
  • Stochastic Oscillator
  • CSPI 7.01
  • PBYI 6.62

Stock Price Comparison Chart: CSPI vs PBYI

CSPI
PBYI
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025April0246810121416182022242628CSPI VS PBYI

About CSPI CSP Inc.

CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use